How to manage postmenopausal osteoporosis?
- PMID: 22338309
- DOI: 10.2143/ACB.66.6.2062612
How to manage postmenopausal osteoporosis?
Abstract
Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased fracture risk. Several therapeutic agents are now available to treat postmenopausal osteoporosis and prevent fractures. Combined calcium and vitamin D supplementation reduce the relative risk of non-vertebral fractures by about 18%. Hormone replacement therapy (HRT) should not be prescribed for osteoporosis in women who do not experience menopausal symptoms. The marked benefits of raloxifene on the reduction in invasive breast cancer and vertebral fracture risk are partially counterbalanced by a lack of effect on non-vertebral fracture risk, and an increased risk of venous thromboembolism and stroke. All four bisphosphonates available in Belgium, except ibandronate, have been shown to reduce the risk of vertebral, non-vertebral and hip fractures in prospective, placebo-controlled trials. Globally, the incidence of vertebral fractures is reduced by 41%-70%, and the incidence of non-vertebral fractures by 25%-39%. The anti-fracture efficacy of weekly or monthly doses of oral bisphosphonates has not been directly shown but is assumed from bridging studies based on BMD changes. To date, the various bisphosphonates have not been studied in head-to-head comparative trials with fracture endpoints. There are potential concerns that long-term suppression of bone turnover associated with bisphosphonate treatment may eventually lead to adverse effects, especially atypical femoral fractures and osteonecrosis of the jaw, but these cases are extremely rare. Teri-paratide (recombinant human 1-34 PTH) administered by daily subcutaneous injections decreases by 65% the relative risk of new vertebral fractures in patients with severe osteoporosis. Pivotal trials with strontium ranelate have shown a 41% reduction in new vertebral fractures and a 16% reduction in non-vertebral fractures over 3 years. Denosumab is a fully human monoclonal antibody to RANK Ligand that is administered as a 60-mg subcutaneous injection every 6 months. In the pivotal phase III trial, there was a 68% reduction in the incidence of new vertebral fractures, whereas the incidence of non-vertebral fractures was reduced by 20%. Several new approaches are being explored, including antibodies to sclerostin, cathepsin K inhibitors, src kinase inhibitors, and drugs that act on calcium sensing receptors.
Similar articles
-
Management of postmenopausal osteoporosis and the prevention of fractures.Panminerva Med. 2014 Jun;56(2):115-31. Epub 2014 Jun 19. Panminerva Med. 2014. PMID: 24942322
-
New developments in the treatment of osteoporosis.Acta Obstet Gynecol Scand. 2013 Jun;92(6):620-36. doi: 10.1111/j.1600-0412.2012.01473.x. Acta Obstet Gynecol Scand. 2013. PMID: 22646526 Review.
-
EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.Maturitas. 2012 Feb;71(2):194-8. doi: 10.1016/j.maturitas.2011.11.010. Epub 2011 Dec 15. Maturitas. 2012. PMID: 22176952 Review.
-
Developments in the pharmacotherapeutic management of osteoporosis.Expert Opin Pharmacother. 2006 Aug;7(12):1603-15. doi: 10.1517/14656566.7.12.1603. Expert Opin Pharmacother. 2006. PMID: 16872263 Review.
-
[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].Z Rheumatol. 2003 Dec;62(6):512-7. doi: 10.1007/s00393-003-0560-5. Z Rheumatol. 2003. PMID: 14685711 Review. German.
Cited by
-
Dietary Collagen Hydrolysates Retard Estrogen Deficiency-Induced Bone Loss through Blocking Osteoclastic Activation and Enhancing Osteoblastic Matrix Mineralization.Biomedicines. 2022 Jun 10;10(6):1382. doi: 10.3390/biomedicines10061382. Biomedicines. 2022. PMID: 35740404 Free PMC article.
-
MiR-135-5p promotes osteoblast differentiation by targeting HIF1AN in MC3T3-E1 cells.Cell Mol Biol Lett. 2019 Aug 8;24:51. doi: 10.1186/s11658-019-0177-6. eCollection 2019. Cell Mol Biol Lett. 2019. PMID: 31410089 Free PMC article.
-
Decreased microRNA-182-5p helps alendronate promote osteoblast proliferation and differentiation in osteoporosis via the Rap1/MAPK pathway.Biosci Rep. 2018 Dec 21;38(6):BSR20180696. doi: 10.1042/BSR20180696. Print 2018 Dec 21. Biosci Rep. 2018. Retraction in: Biosci Rep. 2024 Aug 28;44(8):BSR-2018-0696_RET. doi: 10.1042/BSR-2018-0696_RET. PMID: 30413613 Free PMC article. Retracted.
-
Investigation of candidate genes and mechanisms underlying postmenopausal osteoporosis using bioinformatics analysis.Mol Med Rep. 2018 Jan;17(1):1561-1572. doi: 10.3892/mmr.2017.8045. Epub 2017 Nov 14. Mol Med Rep. 2018. PMID: 29138843 Free PMC article.
-
Effect of periodontitis on the development of osteoporosis: results from a nationwide population-based cohort study (2003-2013).BMC Womens Health. 2017 Sep 11;17(1):77. doi: 10.1186/s12905-017-0440-9. BMC Womens Health. 2017. PMID: 28893226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous